Eagle Harbor Asset Management’s Corcept Therapeutics CORT Stock Holding History

Eagle Harbor Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Buy	+4,000	New	+$242K	0.27%	101

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eagle Harbor Asset Management's CORT Position: Q2 2026 in Review

Eagle Harbor Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4,000 shares worth $348K. The stake represents 0.27% of the portfolio and ranks #101 among its holdings.

420 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Eagle Harbor Asset Management held 4,000 shares of Corcept Therapeutics worth $348K as of Q2 2026.
Corcept Therapeutics was a new Eagle Harbor Asset Management position in Q2 2026.
Corcept Therapeutics made up 0.27% of Eagle Harbor Asset Management's portfolio in Q2 2026, its #101 holding.
420 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Eagle Harbor Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.